AstraZeneca PLC on Wednesday said its MedImmune research and development arm has secured orphan drug designation for its MEDI-551 drug from the US Food & Drug Administration.
The drugmaker said MEDI-551 is used to treat patients with neuromyelitis optica, an autoimmune disease of the central nervous system by which the body’s immune system attacks healthy cells, most commonly in the optic nerves and spinal cord.
{iframe}http://www.lse.co.uk/AllNews.asp?code=p1anyzet&headline=AstraZenecas_MedImmune_Gets_Orphan_Designation_For_MEDI551_Treatment{/iframe}